In the earliest years of the HIV/AIDS pandemic, doctors and researchers faced a terrifying medical crisis with very few tools available. By the mid-1980s, HIV infection had already claimed thousands of lives worldwide, particularly among gay men, haemophiliacs, intravenous drug users, and recipients of contaminated blood products. Patients often progressed from HIV infection to AIDS rapidly, developing opportunistic infections and cancers that the immune system could no longer fight. Amid fear, stigma, and desperation, the first generation of HIV treatments emerged. Central among these was the use of monotherapy — the treatment of HIV with a single antiretroviral drug.

At the time, monotherapy represented hope. It was the first real attempt to directly suppress HIV replication. Yet while it initially appeared promising, the limitations of single-drug therapy soon became clear. The history of HIV monotherapy is therefore both a story of medical innovation and a cautionary lesson about viral resistance, toxicity, and the complexity of treating chronic viral infections.

The first widely used HIV drug was Zidovudine, also known as AZT. Approved in 1987, AZT belonged to a class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs). It worked by interfering with reverse transcriptase, an enzyme HIV needs in order to reproduce inside human cells. For the first time, clinicians had a medication capable of slowing viral replication.

The arrival of AZT was hailed as a breakthrough. In the context of a disease that was almost universally fatal, even modest improvements were seen as extraordinary. Early clinical trials suggested that AZT could prolong life, reduce opportunistic infections, and improve quality of life in some patients. Hospitals that had previously been overwhelmed with dying AIDS patients saw individuals temporarily stabilise or regain strength. For many people living with HIV, AZT symbolised survival and hope in a period dominated by grief and uncertainty.

However, the benefits of monotherapy were limited and often temporary. HIV is a retrovirus that mutates extremely rapidly. Because monotherapy relied on only one drug attacking one part of the viral replication cycle, HIV could adapt relatively quickly. Resistant strains of the virus emerged, sometimes within months of treatment beginning. Once resistance developed, the medication lost much of its effectiveness.

This rapid development of resistance was one of the greatest drawbacks of monotherapy. Doctors would often observe an initial improvement in patients, followed by renewed immune decline as the virus rebounded. Viral load testing was not yet routinely available in the late 1980s, so clinicians often relied on falling CD4 cell counts and worsening symptoms to recognise treatment failure. By the early 1990s, researchers increasingly understood that HIV could evolve around single-drug treatments with alarming speed.

Another major drawback was toxicity. AZT in particular was associated with substantial side effects, especially at the high doses initially prescribed. Patients frequently experienced nausea, headaches, fatigue, insomnia, and muscle pain. More serious complications included anaemia and bone marrow suppression, which sometimes became severe enough to require blood transfusions. Some patients found the treatment nearly as debilitating as the disease itself.

The dosing schedule also posed challenges. Early AZT regimens required patients to take pills every four hours, including throughout the night. Adherence was difficult, particularly for individuals already coping with illness, poverty, discrimination, or mental health challenges. Missing doses could further encourage drug resistance.

Despite these drawbacks, monotherapy did produce important benefits beyond immediate patient outcomes. It demonstrated conclusively that HIV itself was the cause of AIDS and that suppressing viral replication could improve health. This may seem obvious today, but during the 1980s there remained fringe theories and misinformation disputing the viral cause of AIDS. The partial success of AZT and similar drugs reinforced the scientific understanding of HIV pathogenesis.

Monotherapy also accelerated pharmaceutical research. Following AZT, other NRTI drugs such as Didanosine, Zalcitabine, and Stavudine entered clinical use. Although many were still used individually at first, researchers increasingly experimented with combining drugs. Clinical experience with monotherapy made it clear that HIV treatment needed a more aggressive and sustained approach.

By the mid-1990s, the concept of combination therapy had become central to HIV medicine. Scientists recognised that using multiple drugs simultaneously made it much harder for HIV to mutate and escape treatment. This led to the development of Highly Active Antiretroviral Therapy (HAART), introduced in 1996. HAART typically combined three drugs from at least two different classes, dramatically reducing viral load and transforming HIV from a near-certain death sentence into a manageable chronic condition for many people.

The failure of monotherapy therefore directly contributed to one of the greatest medical advances of the twentieth century. Researchers learned that HIV could not be effectively controlled by a single agent because of the virus’s extraordinary genetic variability. Combination therapy attacked HIV at multiple stages of replication, reducing the likelihood of resistance and producing much more durable viral suppression.

Nevertheless, it would be unfair to dismiss monotherapy as a complete failure. In historical context, these treatments emerged during a period of fear and desperation unlike almost any other in modern medicine. Patients were dying rapidly, often abandoned by governments and stigmatised by society. Activists demanded faster drug approvals and expanded access to experimental therapies. In that environment, even temporary benefits mattered deeply.

Monotherapy also gave patients time. For some individuals, AZT and other early drugs extended survival long enough for them to later access combination therapies that became available in the mid-1990s. Many long-term HIV survivors today lived through the monotherapy era and credit those early treatments with helping them survive until better therapies emerged.

The era also reshaped the relationship between patients, activists, researchers, and regulatory agencies. Groups such as ACT UP challenged government inaction and pushed for accelerated research, compassionate drug access, and patient involvement in clinical trial design. Their activism profoundly influenced how modern drug approval systems operate, particularly during public health emergencies.

Today, monotherapy is generally not recommended for HIV treatment because modern evidence overwhelmingly supports combination antiretroviral therapy. Current HIV medications are far safer, more effective, and easier to take than early AZT regimens. Many patients now achieve undetectable viral loads with one pill daily, allowing them to live long and healthy lives.

Still, the history of HIV monotherapy remains critically important. It reflects both the urgency and the limitations of early medical responses to the AIDS crisis. It illustrates how science progresses through trial, error, and hard-earned lessons. Above all, it reminds us of the courage of the patients, doctors, nurses, and activists who confronted HIV in its darkest years, often with little more than hope and an imperfect single drug.

Tim Alderman ©️2026